Research into ENA-001 is also supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) under award number R44DA057133. The content of this document is the ...

Funding from the NIH's National Institute on Drug Abuse (NIDA) will Support Development of ENA-001, an Agnostic Respiratory Stimulant, for Community Drug Overdose and as a Medical ...

Funding from the NIH's National Institute on Drug Abuse (NIDA) will Support Development of ENA-001, an Agnostic Respiratory Stimulant, for Community Drug Overdose and as a Medical Countermeasure PRINC ...

[77] Bolus doses in the range of 625 mg to 2.5 g (12.5–50 mg/kg) have been fatal. Premixed injection solutions are available and may help reduce dosage errors. For patients on diuretic therapy ...

We set the dosing regimen as 1 mg/kg intravenous bolus followed by 5 mg/kg/day continuous intraperitoneal injection for 72 hours. We compared a composite neurological score, and rotarod performance ...

Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...

By Alan Cowell The Aga Khan IV, who as the leader of the world’s Ismaili Muslims fused entrepreneurship and philanthropy in becoming one of the world’s wealthiest hereditary rulers ...

Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including ...

Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD, Mass., Feb.